Drug updated on 4/16/2024
| Dosage Form | Injection (intravenous; 74 MBq/mL [2 mCi/mL]) |
| Drug Class | Radioactive diagnostic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with suspected Parkinsonian syndromes (PS)
- Indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with suspected dementia with Lewy bodies (DLB)
Summary
- Ioflupane I-123 (DaTscan) is indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single-photon emission computed tomography (SPECT) brain imaging in adult patients with suspected Parkinsonian syndromes and dementia with Lewy bodies.
- Three studies were examined, providing insights into the effectiveness and safety profiles of DaTscan compared to alternative diagnostic methods such as transcranial sonography (TCS).
- The studies highlight that DaTscan shows high effectiveness in differentiating parkinsonian syndromes from other conditions like essential tremor or psychogenic tremor. It provides specific insights into dopamine transporter levels which can be pivotal for certain diagnoses.
- Compared to TCS, while TCS offers similar diagnostic accuracy without radiation exposure, it has a high risk of bias in patient selection methodologies. However, being non-invasive and devoid of radiation makes TCS a viable initial screening tool where DaTscan accessibility might be limited due to cost or availability.
- In terms of impact on management, approximately half the patients had their management plans altered post-DaTscan imaging; about one-third had their diagnoses changed after undergoing this scan. This underscores its value in therapeutic decision-making for suspected Parkinsonian syndrome cases.
- There's a need for further research focusing on specific patient subgroups to understand better how effective DaTscan is across different demographics or disease stages.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| DaTscan (ioflupane I-123) Prescribing Information. | 2022 | GE Healthcare, Arlington Heights, IL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Practical Overview of 123I-Ioflupane Imaging in Parkinsonian Syndromes. | 2024 | Radiographics |
| Differentiating Parkinson's Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis. | 2022 | Journal of Parkinson’s Disease |
| Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: A systematic review and meta-analysis. | 2021 | NPJ Parkinson’s Disease |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| The Diagnostic Pathway of Imaging in Clinical Practice for Parkinsonisms. | 2022 | International Parkinson and Movement Disorder Society |
| CANM guidelines for imaging of the dopamine transport system in evaluation of movement disorders. | 2020 | The Canadian Journal of Nuclear Medicine |
| EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. | 2020 | European Journal of Nuclear Medicine and Molecular Imaging |
| Canadian guideline for Parkinson disease – Executive summary. | 2019 | Canadian Medical Association Journal |
| Canadian guideline for Parkinson disease. | 2019 | Canadian Medical Association Journal |